Ionis Pharmaceuticals unveiled results from a survey conducted by The Harris Poll showing that 91% of surveyed adults living ...

A nylon maker goes bankrupt, a carbon capture start-up raises money, Germany’s Merck acquires SpringWorks, and more ...

After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.

Many companies have foreshadowed deals to come during earnings calls in recent days. The return of M&A would be a welcome ...

Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...

Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in ...

Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...

SpringWorks sells two rare tumors drugs in the US and has two precision oncology drugs in early-stage development.

Merck KGaA plans to acquire SpringWorks Therapeutics (NASDAQ:SWTX) for approximately $3.9 billion, aiming to enhance its ...

A German pharmaceutical company is acquiring a drug developer with operations in Research Triangle Park.

Current health news highlights include a dispute over EU drug pricing proposals, a U.S.-Mexico accord on screwworm management ...